Mr. Crawford has held multiple leadership positions in gene editing and drug discovery companies. While serving as VP of Business Development at Transposagen, Jack was instrumental in laying the foundation for commercial applications of the piggyBac transposase, now being used around the globe in capacities ranging from basic research to clinical cell therapy.
At Hera BioLabs, he successfully led a complete business pivot to spear-heading the first fully immunodeficient gene edited rat models for oncology xenografts. At Demeetra Jack is focusing on providing partners with commercially applicable gene editing technologies with simple accessible licenses, as well as developing cannabinoid-based therapeutics.
Mr. Crawford holds a Bachelor of Science in Biochemistry from Virginia Tech and a Master’s in Biotechnology from University of Pennsylvania.
At Hera BioLabs, he successfully led a complete business pivot to spear-heading the first fully immunodeficient gene edited rat models for oncology xenografts. At Demeetra Jack is focusing on providing partners with commercially applicable gene editing technologies with simple accessible licenses, as well as developing cannabinoid-based therapeutics.
Mr. Crawford holds a Bachelor of Science in Biochemistry from Virginia Tech and a Master’s in Biotechnology from University of Pennsylvania.
Speaking In
10:30 AM - 10:45 AM
Tuesday, June 6
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
